Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity

NCT07754045 is registered in ClinicalTrials.gov with Lumos Pharma as lead sponsor.

NCT NCT07754045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07754045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity
Lead sponsor
Lumos Pharma
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 15, 2027
Completion date
February 15, 2028
Enrollment
202 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight